CLL Coverage from Every Angle
Editor:
Jennifer R. Brown, MD, PhD
Advertisement
Advertisement

Recent News

Bolstering Immunity With Infection Prophylaxis in CLL
Are B-Cell Receptor Stereotypes Indicative of Patient Outcomes in CLL?
What Is the Best Method for Assessing Splenic Volume in Patients With CLL?
BTK Inhibitors for CLL: International Consensus for Managing Cardiovascular Risk
Defining the Role of PAK1 in Ibrutinib-Resistant CLL
Genetic Underpinnings of CLL Relapse During Venetoclax Treatment
Identifying Genetic Factors of CLL Via Perhaps the Most Comprehensive Molecular Map Yet
Long-Term Follow-up on Use of Venetoclax in Patients With CLL and 17P Deletion
Long-Term Outcomes With Chemoimmunotherapy Regimen in IGHV-Mutated CLL
Next-Generation Sequencing and Its Prognostic Value for Patients With CLL
Real-World Findings in Patients With CLL Treated With Both BTK and BCL2 Inhibitors
Impact of Ibrutinib Plus Venetoclax on Measurable Residual Disease Negativity Rates in CLL
CLL14 Trial of Venetoclax Plus Obinutuzumab: Update After 5 Years Off Treatment
5-Year Follow-up of ELEVATE-TN: Obinutuzumab-Based Regimens for CLL
How Do Quality-of-Life Indicators Differ Between BTK Inhibitor Types in CLL?
Perceptions of Illness and Psychological Outcomes in Patients With CLL
Time-Limited Targeted Therapy Versus Chemoimmunotherapy in CLL
Study Identifies New Prognostic Marker for Patients With CLL
FDA Warns of Potential Increased Risks With Use of Kinase Inhibitor Duvelisib
Umbrella Analysis of B-Cell Therapies for Chronic Lymphocytic Leukemia
ASCO 2022: Study Sheds Light on Richter’s Syndrome in Patients With CLL
ASCO 2022: How Informed Are Patients With CLL in North America and the European Union?
ASCO 2022: Novel BCL2 Inhibitor Under Study in Treatment of Resistant CLL
ASCO 2022: Racial/Ethnic Identity and Overall Survival for Patients With CLL
ASCO 2022: Extended Follow-up With Obinutuzumab, Ibrutinib, and Venetoclax in CLL
ASCO 2022: 3-Year Follow-up on Fixed-Duration Ibrutinib/Venetoclax in First-Line Setting in CLL
MicroRNA Modulation of the TGF-β Pathway in CLL: Novel Molecular Connection?
Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.